AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With ...
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.
Berenberg Bank Sticks to Its Buy Rating for AstraZeneca (AZN)
Berenberg Bank analyst Luisa Hector maintained a Buy rating on AstraZeneca (AZN – Research Report) yesterday and set a price target of £140.00.
AstraZeneca (AZN) Gets a Buy from Bernstein
In a report released on February 24, Florent Cespedes from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
Medpage Today on MSN23 小时
Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers
"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
Gastrointestinal Cancer Research: Comprehensive Conference Coverage for Competitive ...
A case study on how one of the leading pharma companies in the oncology space approached DelveInsight with a pressing need for conference coverage to monitor the activities and data readouts of ...